Rhythm AI has appointed Mike Dineen as its new CEO, marking a significant leadership transition for the company as it advances its Star Apollo mapping software.
Dineen brings over 30 years of experience in the medtech sector, particularly in cardiovascular technologies. He has a history of guiding innovations from initial development through to market launch and acquisition. Before joining Rhythm AI, he co-founded and led Tioga Cardiovascular, where he worked on a transcatheter mitral valve replacement system. His previous roles include CEO of Kalila Medical, which he led to regulatory success and acquisition by Abbott, and various senior positions at other notable medtech firms.
His appointment comes at a crucial time for Rhythm AI, as the company has recently received FDA 510(k) clearance for its Star Apollo system, which integrates with major mapping platforms used in electrophysiology labs. Dineen’s focus will be on accelerating the adoption of Star Apollo, enhancing clinical evidence for physician uptake, and establishing vital partnerships to ensure the technology reaches those who need it.
With Dineen's extensive background and strategic vision, Rhythm AI aims to solidify its presence in the atrial fibrillation ablation market. His leadership is expected to help navigate the complexities of commercialization and expand access for physicians and patients alike.